AVOS Large Cap Pharma Performance Outlooks
What are Large Cap Pharma Performance Outlooks?
AVOS Life Sciences' Large Cap Pharma Performance Outlooks (LCPPO) consist of an analytical framework that has been employed extensively as an Investor Relations, Corporate Strategy, and Business Development tool, tracking performance in the large cap pharmaceutical sector. LCPPO is without peer in the world of consensus sell-side investment analysis - for the integrity of its data, the soundness of its method, and the intellectual rigor of its market metrics and assumptions.
The analytical framework utilized in LCPPO is based on a proprietary algorithm and scoring convention that highlights six Strategic Performance metrics that have, independently and in combination, shown meaningful correlation to changes in market capitalization. Employing an extensive database of historical results and current investment sell-side analyst forecasts, LCPPO tracks market perceptions around performance catalysts and their impact on the major Rx drug Portfolio and specific product sales trends of 14 large cap pharma companies. LCPPO delivers novel insights into the key inflection points of strategic performance. As such, it is an indispensable tool for competitive benchmarking and scenario analysis.
The AVOS LCPPO framework has been validated by users within the pharma/biotech industry and by AVOS professionals over the past 10 years. Senior management at one of the world's largest pharmaceutical companies has depended on the AVOS LCPPO model for its novel analytics and incisive conclusions.
Companies included in the LCPPO Major Pharmaceutical Peer Group:
- Abbott Laboratories (ABT)
- Amgen (AMGN)
- AstraZeneca (AZN)
- Bristol-Myers Squibb (BMY)
- Eli Lilly (LLY)
- GlaxoSmithKline (GSK)
- Johnson & Johnson (JNJ)
- Merck & Co (MRK)
- Novartis (NVS)
- Pfizer (PFE)
- Roche (ROCHE)
- Sanofi-Aventis (SNY)
- Schering-Plough (SGP)
- Wyeth (WYE)
